Eli Lilly to acquire Merida Biosciences for $2.9 billion

Eli Lilly announced an agreement to acquire Merida Biosciences, a private biopharmaceutical company, for $2.9 billion in cash. The acquisition represents the latest in a series of strategic deals to expand Lilly's pipeline across multiple therapeutic areas, building on the company's ongoing aggressive approach to business development and internal innovation.

1. Eli Lilly announced the acquisition of Merida Biosciences for $2.9 billion in cash on Monday, August 31, 2026.
2. The acquisition is part of Lilly's broader strategy to expand its drug pipeline through targeted M&A activity.